Fri Jul 03, 2020 16:25
Fri Jul 03, 2020 16:23
Background Physical activity (PA) is recommended for women with breast cancer (BC); however, data are sparse on the association of PA with quality of life (QOL) and patient‐reported symptoms for women on adjuvant endocrine therapy (AET). Methods Women with hormone receptor–positive BC who were taking AET completed standardized surveys about their health‐related QOL, AET‐related symptoms, and levels of PA using validated measures. A Wald chi‐square test and an analysis of variance were used...
Thu Jul 02, 2020 19:48
Abstract It has been suggested that Fusobacterium nucleatum (Fn) may differentially impact tumor immune responses according to microsatellite instability (MSI) status in colorectal cancers (CRCs). We aimed to reveal the detailed relationship between intratumoral Fn and immune microenvironmental features in MSI-high CRCs. A total of 126 MSI-high CRCs were subjected to analyses for intratumoral Fn DNA load using quantitative PCR and for densities of tumor-infiltrating immune cells,...
Sat Jul 04, 2020 03:00
Abstract Dendritic cell (DC)-based vaccines are recognized as a promising immunotherapeutic strategy against cancer; however, the efficacy of immunotherapy with DCs is controlled via immune checkpoints, such as programmed death-ligand 1 (PD-L1). PD-L1 expressed on DC and tumor cells binds to programmed death-1 (PD-1) receptors on the activated T cells, which leads to the inhibition of cytotoxic T cells. Blocking of PD-L1 on DC may lead to improve the efficacy of DC therapy for...
Sat Jul 04, 2020 03:00
Abstract Purpose An improved understanding of RCC immunology should shed further light on RCC tumor biology. Our objective was to study to what extent serum levels of the IL-6 family of cytokines at diagnosis were relevant to survival. Methods A total of 118 consecutively patients with RCC, in which the tumor was surgically removed at Haukeland University...
Fri Jul 03, 2020 03:00
Summary Chemoresistance has become a leading cause of mortality in breast cancer patients and is one of the major obstacles for improving the clinical outcome. Long noncoding RNAs play important roles in breast cancer tumorigenesis and chemoresistance. However, the involvement and regulation of lncRNAs in breast cancer chemoresistance are not completely understood. Here, we reported that Linc00839 was localized in the nucleus and upregulated in chemoresistant BC cells and tissues, and high level...
Fri Jul 03, 2020 17:20
Abstract The rapid spread of COVID‐19 represented the most serious issue to public health globally. Hematological patients as immunocompromised hosts are vulnerable to SARS‐CoV‐2 infection. There is rare information available regarding the clinical features of hematological patients concomitant with COVID‐19. In this study, 9 concomitant patients were analyzed for their clinical manifestations, the laboratory data, radiological findings and immunologic features. The median age was 50 years (range,...
Fri Jul 03, 2020 17:20
Abstract Cancer treatment with a fluoropyrimidine (FP) is often accompanied by severe toxicity that may be dependent on the activity of catalytic enzymes encoded by the DPYD , DPYS and UPB1 genes. Genotype‐guided dose individualization of FP therapy has been proposed in Western countries, but our knowledge of the relevant genetic variants in East Asian populations is presently limited. To investigate the association between these genetic variations and FP‐related high toxicity in a Japanese population,...
Fri Jul 03, 2020 17:20
Abstract Although next‐generation sequencing‐based panel testing is well‐practiced in the field of cancer medicine for the identification of target molecules in solid tumors, the clinical utility and clinical issues surrounding panel testing in hematological malignancies have yet to be fully evaluated. We conducted a multicenter prospective clinical‐sequencing study to verify the feasibility of a panel test for hematological tumors, including acute myeloid leukemia, acute lymphoblastic leukemia,...
Fri Jul 03, 2020 17:20
Abstract The ongoing, Phase Ib MONALEESASIA study is evaluating the efficacy and safety of ribociclib plus endocrine therapy in Asian patients with hormone receptor‐positive, human epidermal growth factor receptor 2‐negative advanced breast cancer. Eligible patients from Japan, Hong Kong, and Singapore were enrolled in this 2‐phase study consisting of a dose‐escalation phase to determine the maximum‐tolerated dose and the recommended Phase II dose of ribociclib plus letrozole, and a dose‐expansion...
Fri Jul 03, 2020 17:20
Opinion statement Denosumab is a RANK ligand inhibitor approved for the treatment of giant cell tumor of bone. While the role of denosumab in the setting of advanced and unresectable disease is well established, its role in surgically resectable disease is currently under discussion. Several prospective and retrospective series on neoadjuvant therapy in potentially resectable tumor with high morbidity surgery reported a relapse rate of 10–20% after resection and 30–40% after...
Sat Jul 04, 2020 03:00
Publication date: September 2020Source: European Journal of Cancer, Volume 136Author(s): Benedetta Conte, Marco Bruzzone, Matteo Lambertini, Francesca Poggio, Claudia Bighin, Eva Blondeaux, Michelino De Laurentiis, Enrichetta Valle, Francesco Cognetti, Cecilia Nisticò, Sabino De Placido, Ornella Garrone, Teresa Gamucci, Filippo Montemurro, Fabio Puglisi, Barbara Cardinali, Piero Fregatti, Loredana Miglietta, Francesco Boccardo, Marcello Ceppi
Sun Jul 05, 2020 18:44
Publication date: Available online 4 July 2020Source: European Journal of CancerAuthor(s): K. de Joode, D.W. Dumoulin, V. Engelen, H.J. Bloemendal, M. Verheij, H.W.M. van Laarhoven, I.H. Dingemans, A.C. Dingemans, A.A.M. van der Veldt
Sun Jul 05, 2020 18:44
Publication date: Available online 4 July 2020Source: European Journal of CancerAuthor(s): Ugo De Giorgi, Chiara Casadei, Giuseppe Bronte, Mattia Altini, Giovani Martinelli
Sun Jul 05, 2020 18:44
Publication date: September 2020Source: European Journal of Cancer, Volume 136Author(s): Stefano Cavalieri, Luigi Mariani, Vincent Vander Poorten, Laure Van Breda, Maria C. Cau, Salvatore Lo Vullo, Salvatore Alfieri, Carlo Resteghini, Cristiana Bergamini, Ester Orlandi, Giuseppina Calareso, Paul Clement, Esther Hauben, Francesca Platini, Paolo Bossi, Lisa Licitra, Laura D. Locati
Sat Jul 04, 2020 22:10
Publication date: September 2020Source: European Journal of Cancer, Volume 136Author(s): Maarten J. van der Doelen, Pedro Isaacsson Velho, Peter H.J. Slootbeek, Samhita Pamidimarri Naga, Maren Bormann, Sjoerd van Helvert, Leonie I. Kroeze, Inge M. van Oort, Winald R. Gerritsen, Emmanuel S. Antonarakis, Niven Mehra
Sat Jul 04, 2020 22:10
Publication date: August 2020Source: European Journal of Cancer, Volume 135Author(s): Alessandra Raimondi, Massimo Di Maio, Federica Morano, Salvatore Corallo, Sara Lonardi, Carlotta Antoniotti, Lorenza Rimassa, Andrea Sartore-Bianchi, Marco Tampellini, Giuliana Ritorto, Roberto Murialdo, Matteo Clavarezza, Alberto Zaniboni, Vincenzo Adamo, Gianluca Tomasello, Fausto Petrelli, Lorenzo Antonuzzo, Monica Giordano, Saverio Cinieri, Raffaella Longarini
Fri Jul 03, 2020 15:56
Innovative countermeasures can maintain cancer care continuity during the COVID-19 pandemic in Korea
Publication date: Available online 3 July 2020Source: European Journal of CancerAuthor(s): S. Lee, A.-R. Lim, M.-J. Kim, Y. Ji Choi, J.W. Kim, K.H. Park, S.W. Shin, Y.H. Kim
Fri Jul 03, 2020 15:56
Publication date: Available online 4 July 2020Source: European Journal of Surgical OncologyAuthor(s): Pengliang Wang, Jingyu Deng, Zhe Sun, Wei Wang, Zhenning Wang, Huimian Xu, Zhiwei Zhou, Han Liang
Sun Jul 05, 2020 16:46
Publication date: Available online 4 July 2020Source: European Journal of Surgical OncologyAuthor(s): José Daniel Subiela, Angelo Territo, Asier Mercadé, Josep Balañà, Julia Aumatell, Julio Calderon, Andrea Gallioli, Daniel A. González-Padilla, Josep Maria Gaya, Joan Palou, Alberto Breda
Sat Jul 04, 2020 19:57
Publication date: Available online 4 July 2020Source: European Journal of Surgical OncologyAuthor(s): Antonio V. Sterpetti
Sat Jul 04, 2020 19:57
Publication date: Available online 3 July 2020Source: European Journal of Surgical OncologyAuthor(s): A. Brown, B. Spazzoli, E. Mah, D. May, J. Chu, T. Spelman, P. Choong, C. Di Bella
Sat Jul 04, 2020 19:57
Publication date: Available online 3 July 2020Source: European Journal of Surgical OncologyAuthor(s): Nicholas Farkas, Joshua Wong, Sherif Monib, Simon Thomson
Sat Jul 04, 2020 19:57
Publication date: Available online 3 July 2020Source: European Journal of Surgical OncologyAuthor(s): Gorka Ibarra, Andres Rivera, Borja Fernandez-Ibarburu, David Gurpegui, Ignacio Capdevila
Sat Jul 04, 2020 19:57
Publication date: Available online 3 July 2020Source: European Journal of Surgical OncologyAuthor(s): Tomohiro Fujiwara, Yoichi Kaneuchi, Jonathan Stevenson, Michael Parry, Vineet Kurisunkal, Rhys Clark, Yusuke Tsuda, Minna Laitinen, Robert Grimer, Lee Jeys
Sat Jul 04, 2020 19:57
Publication date: Available online 2 July 2020Source: European Journal of Surgical OncologyAuthor(s): Stéphanie Tock, Jennifer Wallet, Marine Belhadia, Delphine Hudry, Louise Ghesquière, Fabrice Narducci, Eric Leblanc
Fri Jul 03, 2020 16:18
Future Oncology, Ahead of Print.
Fri Jul 03, 2020 12:51
Future Oncology, Ahead of Print.
Fri Jul 03, 2020 04:04
Related Articles Biosimilars in oncology: key role of nurses in patient education. Future Oncol. 2020 Jul 03;: Authors: Waller CF, Friganović A Abstract Biosimilars have the potential to lower costs and increase patient access to life-saving cancer therapies. However, lack of familiarity with biosimilars can be a barrier to their adoption, limiting their health and economic benefits. As highly trusted healthcare providers, nurses play integral...
Sat Jul 04, 2020 16:03
Related Articles GammaTile®: Surgically targeted radiation therapy for glioblastomas. Future Oncol. 2020 Jul 03;: Authors: Gessler DJ, Ferreira C, Dusenbery K, Chen CC Abstract Glioblastoma is the most common primary malignant neoplasm of the central nervous system in adults. Standard of care is resection followed by chemo-radiation therapy. Despite this aggressive approach, >80% of glioblastomas recur in proximity to the resection cavity....
Sat Jul 04, 2020 16:03
Related Articles Long noncoding RNA THOR is highly expressed in colorectal cancer and predicts a poor prognosis. Future Oncol. 2020 Jul 02;: Authors: Chu F, Cui Y, Li K, Xiao X, Zhang L, Zhang L, Wang L, Gao L, Yin N, Wu H Abstract Aim: Colorectal cancer (CRC) is one of the leading causes of cancer-related deaths worldwide. This study aimed to investigate the role of long noncoding RNA THOR in CRC. Materials & methods: The expression of...
Fri Jul 03, 2020 15:48
Related Articles Therapy options after CDK4/6 inhibitors for HR+, HER2- postmenopausal metastatic/recurrent breast cancer in Japan: a role for mammalian target of rapamycin inhibitors? Future Oncol. 2020 Jul 02;: Authors: Nakayama T, Fujisawa F Abstract Despite advances in the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer, the disease is rarely curable. In this review, we focus...
Fri Jul 03, 2020 15:48
Related Articles Different response rates to chemotherapy between Japanese and German esophageal squamous cell carcinoma: patients may be influenced by ERCC1 or ABCB1. Future Oncol. 2020 Jul 02;: Authors: Narumiya K, Bollschweiler E, Hölscher AH, Yamamoto M, Drebber U, Alakus H, Metzger R, Warnecke-Eberz U Abstract Aim: To find out differences in biomarkers between Japanese and German patients responsible for response after neoadjuvant radio/chemotherapy...
Fri Jul 03, 2020 15:48
Abstract Certain population groups are known to have higher than average anal cancer risk, namely persons living with HIV (PLHIV), men who have sex with men (MSM), women diagnosed with HPV‐related gynaecological precancerous lesions or cancer, solid organ transplant recipients (SOTR), and patients with auto‐immune diseases. Our aim was to provide robust and comparable estimates of anal cancer burden across these groups. Summary incidence rates (IR), as cases per 100,000 person‐years (py), were calculated...
Sat Jul 04, 2020 21:50
Abstract More women are surviving after breast cancer due to early detection and modern treatment strategies. Body weight also influences survival. We aimed to characterize associations between postdiagnosis weight change and prognosis in postmenopausal long‐term breast cancer survivors. We used data from a prospective population‐based patient cohort study (MARIE) conducted in two geographical regions of Germany. Breast cancer patients diagnosed 50‐74 years of age with an incident invasive breast...
Sat Jul 04, 2020 21:49
Abstract Little is known about how health insurance policies, particularly in developing countries, influence breast cancer prognosis. Here, we examined the association between individual health insurance and breast cancer‐specific mortality in China. We included 7436 women diagnosed with invasive breast cancer between 2009 and 2016, at West China Hospital, Sichuan University. The health insurance plan of patient was classified as either urban or rural schemes and was also categorized as reimbursement...
Sat Jul 04, 2020 21:48
Abstract Ovarian cancer (OC) remains a leading cause of gynecological cancer‐related death worldwide, characterized by poor 5‐year survival. Molecular markers could serve as crucial tools of personalized prognosis and therapy. Herein, we present miR‐181a as novel predictor of OC prognosis, using five independent OC cohorts. In particular, a screening (n=81) and an institutionally‐independent validation (n=100, OVCAD multicenter study) serous OC (SOC) cohorts were analyzed. Bagnoli et al. 2016 OC179...
Sat Jul 04, 2020 21:47
Sat Jul 04, 2020 21:46
Abstract Recently we reported about exosomes possessing mRNA of suicide gene secreted from mesenchymal stem/stromal cells (MSCs) engineered to express the suicide gene ‐ fused yeast cytosine deaminase::uracil phosphoribosyltransferase (yCD::UPRT). The yCD::UPRT‐MSC exosomes are internalized by tumor cells and intracellularly convert prodrug 5‐fluorocytosine (5‐FC) to cytotoxic drug 5‐fluorouracil (5‐FU). Human tumor cells with the potential to metastasize release exosomes involved in the creation...
Sat Jul 04, 2020 21:45
Abstract This study was performed to determine the frequency of recall for bilateral breast lesions at screening mammography and compare its outcome with respect to unilateral recall. We included 329132 screening mammograms (34889 initial screens and 294243 subsequent screens) from a Dutch screening mammography programme between January 2013 and January 2018. During 2‐year follow‐up, we collected radiological data, pathology reports and surgical reports of all recalled women. At bilateral recall,...
Sat Jul 04, 2020 21:44
Sat Jul 04, 2020 21:44
Abstract Changes in the field of radiation oncology (RO) impacts residency training. Assessing trainee experiences is essential to inform curriculum development. We aim to explore gaps and strengths in current Canadian RO training, as we move towards competency-based medical education (CBME). An online survey was distributed to residents at all Canadian RO training programs. Surveys consisted of 66 open-ended, Likert-scale, matrix-style, and multiple-choice questions, and assessed...
Sat Jul 04, 2020 03:00
Abstract Introduction Immune checkpoint inhibition through PD-1 and CTLA-4 blockade has shown efficacy in some adult malignancies and generated interest in pediatrics, including central nervous system (CNS) tumors. We describe our experience with immune checkpoint inhibition in recurrent/refractory pediatric CNS tumors. Methods We performed a retrospective...
Sun Jul 05, 2020 03:00
Abstract Purpose Extent of resection remains a paramount prognostic factor for long-term outcomes for glioblastoma. As such, supramaximal resection or anatomic lobectomy have been offered for non-eloquent glioblastoma in an attempt to improve overall survival. Here, we conduct a propensity-matched analysis of patients with non-eloquent glioblastoma who underwent either lobectomy or gross total resection of lesion to investigate the...
Sun Jul 05, 2020 03:00
Abstract Oncogenic fusion of the tropomyosin receptor kinase (Trk) receptor family encoded by the NTRK gene has been found in several carcinomas. About ten targeted therapies have been developed and clinical trials are in progress. However, the results of studies on expression of the Trk receptor in HCC have not yet been published. Immunohistochemical staining was performed using anti-TrkA+B+C antibody (ab181560, Abcam) in 288 curatively resected primary HCC samples, and the correlation...
Sat Jul 04, 2020 03:00
Abstract Amplicon-based next generation sequencing (NGS) approaches have been preferentially adopted by the clinical laboratories on the basis of a short turnaround time (TAT) and small DNA input needs. However, little work has been done to assess the amplicon-based NGS methods for copy number variation (CNV) detection in comparison with current standard methods like immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH). The correlation between NGS based CNV...
Fri Jul 03, 2020 03:00
Abstract Objective This study assesses the effectiveness of face‐to‐face group positive psychotherapy for cancer survivors (PPC) compared to its online adaptation, online group positive psychotherapy for cancer survivors (OPPC), which is held via videoconference. A two‐arm, pragmatic RCT was conducted to examine the effects of both interventions on emotional distress, posttraumatic stress (PTSS) and posttraumatic growth (PTG) among cancer survivors and analyze attrition to treatment. Methods...
Fri Jul 03, 2020 15:10
To estimate the efficacy of neoadjuvant chemotherapy (NCT) in stage T3-4N1 nasopharyngeal carcinoma (NPC).
Thu Jul 02, 2020 03:00
Nasopharyngeal carcinoma (NPC) has an unbalanced geographical distribution, with the highest incidence reported in Southeast Asia [1]. There were 129,000 new cases of NPC in 2018 [2] and approximately 70% of them were locoregionally advanced at diagnosis [3]. For patients with locoregionally advanced NPC (LANPC), concurrent chemoradiotherapy (CCRT) with or without induction chemotherapy (ICT) is recommended by the National Comprehensive Cancer Networkguidelines [4].
Sat Jul 04, 2020 03:00
Publication date: August 2020Source: Cancer Epidemiology, Volume 67Author(s): Xiaojuan Hu, Zhiqiang Zhao, Shao-Kai Zhang, Yanhong Luo, Hongmei Yu, Yanbo Zhang
Fri Jul 03, 2020 19:06
Publication date: August 2020Source: Cancer Epidemiology, Volume 67Author(s): Xue-Yan Wang, Jin-Mei Huang, Xue-Ming Lu, Tim J. Harrison, Hua-Bing Liu, Hui-Hua Jia, Zhong-Liao Fang
Fri Jul 03, 2020 19:06
Publication date: Available online 2 July 2020Source: Seminars in OncologyAuthor(s):
Fri Jul 03, 2020 14:50
Publication date: Available online 2 July 2020Source: Seminars in OncologyAuthor(s): Megan Kruse, Jame Abraham
Fri Jul 03, 2020 14:50
Abstract Objective To prospectively compare the interobserver variability of combined transrectal ultrasound (TRUS)/computed tomography (CT)- vs. CT only- vs. magnetic resonance imaging (MRI) only-based contouring of the high-risk clinical target volume (CTVHR) in image-guided adaptive brachytherapy (IGABT) for locally advanced cervical cancer (LACC). Methods ...
Fri Jul 03, 2020 03:00
Abstract Purpose Magnetic resonance imaging (MRI) is routinely used for locoregional staging of rectal cancer and offers promise for the prediction of hematologic toxicity. The present study compares the clinical utility of MRI-based active bone marrow (BMact) delineation with that of CT-based bone marrow total (BMtot) delineation for predicting hematologic toxicity. Methods...
Fri Jul 03, 2020 03:00
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου